ASX:IREN.AX 28 January 2026

IREN Limited stock price hovers near $60 premarket after 15% jump; earnings ahead

IREN Limited shares rose 0.4% to $60.24 in premarket trading Wednesday after surging 14.6% the previous day on heavy volume. The company recently secured a $9.7 billion deal with Microsoft to supply Nvidia-based cloud capacity, with deployments set for its Texas campus through 2026. IREN will report quarterly results on Feb. 5. The stock remains volatile amid rising bitcoin prices and AI infrastructure investments.

28 January 2026

ASX:IREN.AX·Earnings Reports·Stock Market

BioMarin Pharmaceutical Q4 Earnings Lag Peers in Therapeutics Sector
March 20, 2026, 4:06 PM EDT. BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q4 revenues of $874.6 million, a 17% year-on-year increase, beating expectations by 4.8%. However, the company missed full-year earnings per share (EPS) guidance and offered the weakest outlook among its therapeutics peers, causing its stock to tumble 12% to $55.37. Therapeutics stocks overall showed strong performance, beating revenue estimates by 7.1% on average and holding steady post-earnings. Novavax (NASDAQ:NVAX) led the pack with 66.6% revenue growth, surpassing estimates by 57.4%, driving its stock up 2.4% to $9.76. While BioMarin faces challenges including regulatory scrutiny and competition, advancements in precision medicine and rare disease demand boost the sector. Investors watch for operational execution and pipeline progress amid mixed signals.